Biophytis (EPA:ALBPS) | WebDisclosure

Basculer en Français

9815	Companies
196962	Keywords
128009	Articles
104737	Press releases

Home
Companies
Biophytis

REGULATED PRESS RELEASE

published on 07/01/2024 at 07:00, 1 year 7 months ago

Biophy(s a présenté les résultats de l'étude COVA de phase 2-3 dans les formes sévères de Covid-19 lors du WCID à Paris
Biophytis présente les résultats de l'étude COVA de phase 2-3 sur les formes sévères de Covid-19 lors du WCID à Paris. Des résultats positifs de réduction du risque de défaillance respiratoire et de mortalité sont révélés

Biophytis COVID-19 Résultats Positifs Étude COVA Réduction Du Risque De Mortalité
REGULATED PRESS RELEASE

published on 07/01/2024 at 07:00, 1 year 7 months ago

Biophytis presented its Phase 2-3 COVA study results in severe forms of Covid-19 at the WCID in Paris
Biophytis presented positive results of its Phase 2-3 COVA study for severe Covid-19 at WCID in Paris, showing reduction in respiratory failure and death rates

Biophytis COVID-19 Positive Results Phase 2-3 COVA Study
BRIEF

published on 06/25/2024 at 23:05, 1 year 7 months ago

Biophytis Approves All Resolutions at General Meeting

Shareholders Biophytis General Meeting Resolutions
BRIEF

published on 06/25/2024 at 23:05, 1 year 7 months ago

Résultats de l'Assemblée Générale Mixte de Biophytis du 24 juin 2024

Biophytis Assemblée Générale Resolutions Quorum Vote
REGULATED PRESS RELEASE

published on 06/25/2024 at 23:00, 1 year 7 months ago

RESULTS OF THE COMBINED GENERAL MEETING ON JUNE 24, 2024
Biophytis SA announces the approval of all resolutions at the combined general meeting held on June 24, 2024, with significant shareholder participation

Shareholders General Meeting Resolutions Approval Biophytis SA
REGULATED PRESS RELEASE

published on 06/25/2024 at 23:00, 1 year 7 months ago

RÉSULTATS DE L’ASSEMBLÉE GÉNÉRALE MIXTE DU 24 JUIN 2024
Biophytis annonce l'approbation des résolutions lors de l'Assemblée Générale Mixte du 24 Juin 2024. Détails des décisions et perspectives de la société

Biophytis Biotechnologie Assemblée Générale Mixte Approbation Des Résolutions Développement De Traitements
BRIEF

published on 06/20/2024 at 07:05, 1 year 7 months ago

Biophytis accorde à Blanver les droits exclusifs de BIO101 en Amérique Latine

Biophytis Partenariat Amérique Latine BIO101 Blanver
BRIEF

published on 06/20/2024 at 07:05, 1 year 7 months ago

Biophytis Grants Blanver Exclusive Rights to BIO101 in Latin America in Deal Valued at Up to €108 Million

Biophytis Pharmaceuticals Latin America BIO101 Blanver
PRESS RELEASE

published on 06/20/2024 at 07:00, 1 year 7 months ago

Biophytis grants Blanver exclusive rights to BIO101 in Latin America in deal valued at up to €108 Million
Biophytis grants Blanver exclusive rights to BIO101 in Latin America in deal valued at up to €108 million. Agreement includes upfront and milestones payments, double-digit royalties, and collaboration on manufacturing and clinical development

Biophytis Latin America Exclusive Rights Blanver Pharmaceutical Deal
PRESS RELEASE

published on 06/20/2024 at 07:00, 1 year 7 months ago

Biophytis accorde à Blanver les droits exclusifs de BIO101 en Amérique Latine dans un accord pouvant atteindre 108 M€
Biophytis accorde à Blanver les droits exclusifs de BIO101 en Amérique Latine dans un accord pouvant atteindre 108 M€. Accord de licence exclusive pour la commercialisation de BIO101, y compris dans l’obésité et les infections respiratoires

Biophytis Accord BIO101 Blanver Am\u00e9rique Latine

Accesswire

Published on 02/06/2026 at 08:00, 1 hour 25 minutes ago

Caledonia Mining Corporation Plc Non-Executive Director Shareholding Notification
Published on 02/06/2026 at 03:50, 5 hours 35 minutes ago

High Tide Resources annonce des placements privés sans courtier
Published on 02/06/2026 at 02:45, 6 hours 40 minutes ago

High Tide Resources annonce des placements privés sans courtier
Published on 02/06/2026 at 00:57, 8 hours 28 minutes ago

Noram Lithium Announces Closing of Fully Allocated Non-Brokered Financing
Published on 02/06/2026 at 00:00, 9 hours 25 minutes ago

LIR Life Sciences Commences Project Phase 2 Peptide Design Program with Neuland Laboratories

View all ACCESSWIRE

EQS Group

Published on 02/06/2026 at 09:00, 25 minutes ago

Original-Research: 123fahrschule SE (von NuWays AG): BUY
Published on 02/06/2026 at 09:00, 25 minutes ago

Original-Research: tonies SE (von NuWays AG): BUY
Published on 02/06/2026 at 09:00, 25 minutes ago

Official List Notice
Published on 02/06/2026 at 08:15, 1 hour 10 minutes ago

Bechtle posts strong year-end performance
Published on 02/06/2026 at 08:00, 1 hour 25 minutes ago

A stronger and more competitive Ørsted after a defining year with earnings of DKK 25.1 billion within guidance

Les Echos

Published on 02/06/2026 at 07:54, 1 hour 31 minutes ago

ENGIE - Déclaration du nombre total d'actions et de droits de vote au 31 janvier 2026
Published on 02/05/2026 at 19:24, 14 hours 1 minute ago

Minutes of the Combined General Meeting
Published on 02/05/2026 at 19:24, 14 hours 1 minute ago

Compte-Rendu de l’Assemblée Générale Mixte
Published on 02/05/2026 at 19:15, 14 hours 10 minutes ago

ALTAREA : INFORMATION RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET D’ACTIONS COMPOSANT LE CAPITAL SOCIAL
Published on 02/05/2026 at 19:15, 14 hours 10 minutes ago

ALTAREA : DÉCLARATION MENSUELLE DES OPÉRATIONS RÉALISÉES PAR LA SOCIÉTÉ SUR SES PROPRES TITRES JANVIER 2026

View all LES ECHOS COMFI WIRE